Study wrapper · #618
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.
Editor's note
In a rat naloxone-precipitated morphine-withdrawal model, researchers reported that a single injection of Selank, a synthetic tuftsin-analog peptide, at an anxiolytic dose reduced the overall withdrawal-syndrome index by about 40%, significantly attenuated convulsive reactions, ptosis, and posture disturbances, and raised the tactile-sensitivity threshold roughly ninefold versus active controls. Selank was slightly less potent than diazepam. The result fits Selank's described anxiolytic and stress-modulating profile. This is a single-dose, single-model behavioral study in rats with the usual translational limits, and withdrawal-behavior scales are subjective surrogates. These are preclinical findings; human data are needed before any clinical conclusions can be drawn about Selank and opioid withdrawal.
Plain-language abstract
Researchers tested Selank, a synthetic peptide with anti-anxiety properties, in rats going through morphine withdrawal triggered by a blocking drug (naloxone). A single injection of Selank reduced the overall severity of withdrawal by about 40%, notably easing convulsion-like reactions, drooping eyelids, and posture problems, and it made the animals far less sensitive to touch-based discomfort. Selank was slightly weaker than the standard anti-anxiety drug diazepam on these measures. The authors conclude Selank eased the distressing signs of opioid withdrawal in rats, much like diazepam. The abstract reports no adverse events. These are preclinical findings in rats; human studies would be needed before any clinical conclusions about Selank and withdrawal.